| A framework for advancing our understanding of cancer-associated fibroblasts E Sahai, I Astsaturov, E Cukierman, DG DeNardo, M Egeblad, RM Evans, ... Nature Reviews Cancer 20 (3), 174-186, 2020 | 2674 | 2020 |
| Aurora A kinase (AURKA) in normal and pathological cell division AS Nikonova, I Astsaturov, IG Serebriiskii, RL Dunbrack, EA Golemis Cellular and Molecular Life Sciences 70, 661-687, 2013 | 531 | 2013 |
| Synthetic lethal screen of an EGFR-centered network to improve targeted therapies I Astsaturov, V Ratushny, A Sukhanova, MB Einarson, T Bagnyukova, ... Science signaling 3 (140), ra67-ra67, 2010 | 159 | 2010 |
| Defining venous involvement in borderline resectable pancreatic cancer YS Chun, BN Milestone, JC Watson, SJ Cohen, B Burtness, PF Engstrom, ... Annals of surgical oncology 17, 2832-2838, 2010 | 154 | 2010 |
| Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? TV Bagnyukova, IG Serebriiskii, Y Zhou, EA Hopper-Borge, EA Golemis, ... Cancer biology & therapy 10 (9), 839-853, 2010 | 146 | 2010 |
| Molecular pathways: sterols and receptor signaling in cancer L Gabitova, A Gorin, I Astsaturov Clinical Cancer Research 20 (1), 28-34, 2014 | 144 | 2014 |
| Cholesterol pathway inhibition induces TGF-β signaling to promote basal differentiation in pancreatic cancer L Gabitova-Cornell, A Surumbayeva, S Peri, J Franco-Barraza, D Restifo, ... Cancer cell 38 (4), 567-583. e11, 2020 | 128 | 2020 |
| Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast–driven nutritional support and immunosuppression R Francescone, D Barbosa Vendramini-Costa, J Franco-Barraza, ... Cancer discovery 11 (2), 446-479, 2021 | 121 | 2021 |
| Targeting EGFR resistance networks in head and neck cancer V Ratushny, I Astsaturov, BA Burtness, EA Golemis, JS Silverman Cellular signalling 21 (8), 1255-1268, 2009 | 121 | 2009 |
| Regulation of cholesterol biosynthesis and cancer signaling A Gorin, L Gabitova, I Astsaturov Current opinion in pharmacology 12 (6), 710-716, 2012 | 114 | 2012 |
| Mechanisms of tumor resistance to EGFR-targeted therapies EA Hopper-Borge, RE Nasto, V Ratushny, LM Weiner, EA Golemis, ... Expert opinion on therapeutic targets 13 (3), 339-362, 2009 | 113 | 2009 |
| Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis S Winer, I Astsaturov, RK Cheung, L Gunaratnam, V Kubiak, MA Cortez, ... The Journal of Immunology 166 (4), 2831-2841, 2001 | 111 | 2001 |
| Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study N Vijayvergia, PM Boland, E Handorf, KS Gustafson, Y Gong, HS Cooper, ... British journal of cancer 115 (5), 564-570, 2016 | 104 | 2016 |
| Perspectives of HER2-targeting in gastric and esophageal cancer JN Gerson, S Skariah, CS Denlinger, I Astsaturov Expert opinion on investigational drugs 26 (5), 531-540, 2017 | 99 | 2017 |
| Significance of pathologic response to preoperative therapy in pancreatic cancer YS Chun, HS Cooper, SJ Cohen, A Konski, B Burtness, CS Denlinger, ... Annals of surgical oncology 18, 3601-3607, 2011 | 89 | 2011 |
| Selective Raf inhibition in cancer therapy V Khazak, I Astsaturov, IG Serebriiskii, EA Golemis Expert opinion on therapeutic targets 11 (12), 1587-1609, 2007 | 89 | 2007 |
| Aurora kinases in head and neck cancer R Mehra, IG Serebriiskii, B Burtness, I Astsaturov, EA Golemis The lancet oncology 14 (10), e425-e435, 2013 | 87 | 2013 |
| Endogenous sterol metabolites regulate growth of EGFR/KRAS-dependent tumors via LXR L Gabitova, D Restifo, A Gorin, K Manocha, E Handorf, DH Yang, KQ Cai, ... Cell reports 12 (11), 1927-1938, 2015 | 86 | 2015 |
| T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice S Winer, I Astsaturov, RK Cheung, K Schrade, L Gunaratnam, DD Wood, ... The Journal of Immunology 166 (7), 4751-4756, 2001 | 80 | 2001 |
| Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation A Sukhanova, A Gorin, IG Serebriiskii, L Gabitova, H Zheng, D Restifo, ... Cancer discovery 3 (1), 96-111, 2013 | 78 | 2013 |
